1. Pink Sheet
  2. >>Market Access

Medicare Price Inflation Rebates, Part D ‘Redesign’ Proposed In Senate Finance Bill

 
• By Cathy Kelly

Price inflation rebates are expected to generate $50bn in savings over 10 years, according to the Congressional Budget Office.

United States Capitol Building in Washington DC USA

Prescription drugs covered by Medicare Parts D and B would be subject to mandatory rebates if list prices increase faster than inflation in bipartisan legislation unveiled by Senate Finance Committee chair Chuck Grassley, R-IA, and ranking member Ron Wyden, D-OR, on 23 July.

The price inflation provisions, which have been championed by Wyden, would save Medicare $50bn over 10 years, according to the Congressional Budget Office

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.

Will International Prices Influence Medicare Price Negotiation?

 
• By Cathy Kelly

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

More from Market Access